TriangleHEALTH PROFESSIONAL · SOURCE READING
Loss of heterozygosity of 1p and 16q
Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage III Wilms tumor
Therapy was augmented for patients with loss of heterozygosity of 1p and 16q who were enrolled in the AREN0533 (NCT00379340) trial. Patients with stage III and stage IV Wilms tumor with loss of heterozygosity were treated with regimen M. The 4-year EFS rate was 90.2%, and the OS rate was 96.1%, compared with a 4-year EFS rate of 61.3% (P = .001) and a 4-year OS rate of 86.0% (P = .087) for patients in the NWTS-5 trial. The study suggested an improvement in survival, but it was not powered to detect differences in survival.[264][Level of evidence C2]
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice